{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T02:35:30Z","timestamp":1784255730963,"version":"3.55.0"},"reference-count":78,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T00:00:00Z","timestamp":1691539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>Type I interferonopathies are a broad category of conditions associated with increased type I interferon gene expression and include monogenic autoinflammatory diseases and non-Mendelian autoimmune diseases such as dermatomyositis and systemic lupus erythematosus. While a wide range of clinical presentations among type I interferonopathies exists, these conditions often share several clinical manifestations and implications for treatment. Presenting symptoms may mimic non-Mendelian autoimmune diseases, including vasculitis and systemic lupus erythematosus, leading to delayed or missed diagnosis. This review aims to raise awareness about the varied presentations of monogenic interferonopathies to provide early recognition and appropriate treatment to prevent irreversible damage and improve quality of life and outcomes in this unique patient population.<\/jats:p>","DOI":"10.3389\/fped.2023.1169638","type":"journal-article","created":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T09:00:32Z","timestamp":1691571632000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Interferonopathies masquerading as non-Mendelian autoimmune diseases: pattern recognition for early diagnosis"],"prefix":"10.3389","volume":"11","author":[{"given":"Samuel","family":"Gagne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidya","family":"Sivaraman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoghik","family":"Akoghlanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,8,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1098\/rspb.1957.0048","article-title":"Virus interference. I. The interferon","volume":"147","author":"Isaacs","year":"1957","journal-title":"Proc R Soc Lond B Biol Sci"},{"key":"B2","doi-asserted-by":"publisher","first-page":"873","DOI":"10.3389\/fimmu.2017.00873","article-title":"The role of interferons in inflammation and inflammasome activation","volume":"8","author":"Kopitar-Jerala","year":"2017","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1146\/annurev-immunol-032414-112227","article-title":"Molecular mechanisms in genetically defined autoinflammatory diseases: disorders of amplified danger signaling","volume":"33","author":"de Jesus","year":"2015","journal-title":"Annu Rev Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1749-6632.2011.06220.x","article-title":"Type I interferonopathies: a novel set of inborn errors of immunity","volume":"1238","author":"Crow","year":"2011","journal-title":"Ann N Y Acad Sci"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1084\/jem.20161596","article-title":"Type I interferon-mediated monogenic autoinflammation: the type I interferonopathies, a conceptual overview","volume":"213","author":"Rodero","year":"2016","journal-title":"J Exp Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1309\/AJCP66QIMFARLZKI","article-title":"Degos disease: a C5b-9\/interferon-alpha-mediated endotheliopathy syndrome","volume":"135","author":"Magro","year":"2011","journal-title":"Am J Clin Pathol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nrrheum.2018.31","article-title":"Type I interferon in rheumatic diseases","volume":"14","author":"Muskardin","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"631329","DOI":"10.3389\/fped.2021.631329","article-title":"Type I interferonopathies in children: an overview","volume":"9","author":"d\u2019Angelo","year":"2021","journal-title":"Front Pediatr"},{"key":"B9","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41577-021-00633-9","article-title":"The type I interferonopathies: 10 years on","volume":"22","author":"Crow","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"864","DOI":"10.3390\/biomedicines11030864","article-title":"Optimal selection of Ifn-alpha-inducible genes to determine type I interferon signature improves the diagnosis of systemic lupus erythematosus","volume":"11","author":"Demers-Mathieu","year":"2023","journal-title":"Biomedicines"},{"key":"B11","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/nri3850","article-title":"Aicardi-Goutieres syndrome and the type I interferonopathies","volume":"15","author":"Crow","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1172\/JCI98814","article-title":"Jak1\/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies","volume":"128","author":"Sanchez","year":"2018","journal-title":"J Clin Invest"},{"key":"B13","doi-asserted-by":"publisher","first-page":"176","DOI":"10.21037\/atm-20-6198","article-title":"Sting-Associated vasculopathy with onset in infancy: a familial case series report and literature review","volume":"9","author":"Wang","year":"2021","journal-title":"Ann Transl Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","article-title":"The emerging safety profile of jak inhibitors in rheumatic disease","volume":"13","author":"Winthrop","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1056\/NEJMc1302135","article-title":"Progressive multifocal leukoencephalopathy associated with ruxolitinib","volume":"369","author":"Wathes","year":"2013","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1312625","article-title":"Activated sting in a vascular and pulmonary syndrome","volume":"371","author":"Liu","year":"2014","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"11932","DOI":"10.1038\/ncomms11932","article-title":"Activation of sting requires palmitoylation at the Golgi","volume":"7","author":"Mukai","year":"2016","journal-title":"Nat Commun"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.jaci.2020.06.032","article-title":"A novel sting1 variant causes a recessive form of sting-associated vasculopathy with onset in infancy (savi)","volume":"146","author":"Lin","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1016\/j.cell.2014.12.001","article-title":"Dual proteolytic pathways govern glycolysis and immune competence","volume":"159","author":"Lu","year":"2014","journal-title":"Cell"},{"key":"B20","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.jaip.2020.11.007","article-title":"Overview of sting-associated vasculopathy with onset in infancy (savi) among 21 patients","volume":"9","author":"Fremond","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B21","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/j.1469-8749.2012.04437.x","article-title":"Recognizable phenotypes associated with intracranial calcification","volume":"55","author":"Livingston","year":"2013","journal-title":"Dev Med Child Neurol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/ng.3279","article-title":"Copa mutations impair Er-Golgi transport and cause hereditary autoimmune-mediated lung disease and arthritis","volume":"47","author":"Watkin","year":"2015","journal-title":"Nat Genet"},{"key":"B23","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.clim.2017.10.001","article-title":"Type I interferon pathway activation in Copa syndrome","volume":"187","author":"Volpi","year":"2018","journal-title":"Clin Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e20201045","DOI":"10.1084\/jem.20201045","article-title":"A defect in copi-mediated transport of sting causes immune dysregulation in Copa syndrome","volume":"217","author":"Deng","year":"2020","journal-title":"J Exp Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e20200600","DOI":"10.1084\/jem.20200600","article-title":"Mutations in Copa lead to abnormal trafficking of sting to the Golgi and interferon signaling","volume":"217","author":"Lepelley","year":"2020","journal-title":"J Exp Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s10875-021-00974-z","article-title":"Sting-Mediated lung inflammation and beyond","volume":"41","author":"Fremond","year":"2021","journal-title":"J Clin Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s10875-016-0271-8","article-title":"Copa syndrome: a novel autosomal dominant immune dysregulatory disease","volume":"36","author":"Vece","year":"2016","journal-title":"J Clin Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"00017-2018","DOI":"10.1183\/23120541.00017-2018","article-title":"Analysis of pulmonary features and treatment approaches in the Copa syndrome","volume":"4","author":"Tsui","year":"2018","journal-title":"ERJ Open Res"},{"key":"B29","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s00247-017-3961-3","article-title":"Imaging findings of Copa syndrome in a 12-year-old boy","volume":"48","author":"Noorelahi","year":"2018","journal-title":"Pediatr Radiol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1136\/jmedgenet-2018-105560","article-title":"Expanding the phenotype of Copa syndrome: a kindred with typical and atypical features","volume":"56","author":"Taveira-DaSilva","year":"2019","journal-title":"J Med Genet"},{"key":"B31","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1002\/ppul.24680","article-title":"Lymphocytic interstitial pneumonia and follicular bronchiolitis in children: a registry-based case series","volume":"55","author":"Prenzel","year":"2020","journal-title":"Pediatr Pulmonol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/j.kint.2022.02.031","article-title":"Type I interferon-related kidney disorders","volume":"101","author":"Lodi","year":"2022","journal-title":"Kidney Int"},{"key":"B33","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s10875-020-00832-4","article-title":"Persistent unexplained transaminitis in Copa syndrome","volume":"41","author":"Thaivalappil","year":"2021","journal-title":"J Clin Immunol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.jaip.2020.10.019","article-title":"Effective sirolimus treatment of 2 Copa syndrome patients","volume":"9","author":"Guan","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5152\/eurjrheum.2019.18177","article-title":"Baricitinib in therapy of Copa syndrome in a 15-year-old girl","volume":"7","author":"Krutzke","year":"2019","journal-title":"Eur J Rheumatol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1136\/thoraxjnl-2019-213892","article-title":"Use of ruxolitinib in Copa syndrome manifesting as life-threatening alveolar haemorrhage","volume":"75","author":"Fremond","year":"2020","journal-title":"Thorax"},{"key":"B37","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41525-021-00196-7","article-title":"Stat1 gain-of-function heterozygous cell models reveal diverse interferon-signature gene transcriptional responses","volume":"6","author":"Scott","year":"2021","journal-title":"NPJ Genom Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s10875-020-00847-x","article-title":"Human Stat1 gain-of-function heterozygous mutations: chronic mucocutaneous candidiasis and type I interferonopathy","volume":"40","author":"Okada","year":"2020","journal-title":"J Clin Immunol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/eji.201847955","article-title":"Interferon signature in patients with Stat1 gain-of-function mutation is epigenetically determined","volume":"49","author":"Kaleviste","year":"2019","journal-title":"Eur J Immunol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"3154","DOI":"10.1182\/blood-2015-11-679902","article-title":"Heterozygous Stat1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype","volume":"127","author":"Toubiana","year":"2016","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","first-page":"5638","DOI":"10.1007\/s00415-022-11131-w","article-title":"Cerebral aneurysm in three pediatric patients with Stat1 gain-of-function mutations","volume":"269","author":"Bierman-Chow","year":"2022","journal-title":"J Neurol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ijcard.2015.05.183","article-title":"Recurrent inflammatory aortic aneurysms in chronic mucocutaneous candidiasis with a gain-of-function Stat1 mutation","volume":"196","author":"Tanimura","year":"2015","journal-title":"Int J Cardiol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.1007\/s10067-022-06295-9","article-title":"Childhood-onset Takayasu arteritis and immunodeficiency: case-based review","volume":"41","author":"Sener","year":"2022","journal-title":"Clin Rheumatol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3899\/jrheum.180210","article-title":"An adult fatal case with a Stat1 gain-of-function mutation associated with multiple autoimmune diseases","volume":"46","author":"Maeshima","year":"2019","journal-title":"J Rheumatol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1093\/rheumatology\/key445","article-title":"Monogenic mimics of Behcet's disease in the young","volume":"58","author":"Papadopoulou","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"B46","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12969-021-00552-y","article-title":"Genetic and immunologic findings in children with recurrent aphthous stomatitis with systemic inflammation","volume":"19","author":"Girardelli","year":"2021","journal-title":"Pediatr Rheumatol Online J"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s10875-022-01257-x","article-title":"Impact of jak inhibitors in pediatric patients with Stat1 gain of function (Gof) mutations-10 children and review of the literature","volume":"42","author":"Deya-Martinez","year":"2022","journal-title":"J Clin Immunol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/j.jaci.2018.07.020","article-title":"Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (Stat1) or Stat3 mutations","volume":"142","author":"Forbes","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/art.33368","article-title":"Mutations in proteasome subunit Beta type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity","volume":"64","author":"Liu","year":"2012","journal-title":"Arthritis Rheum"},{"key":"B50","doi-asserted-by":"publisher","first-page":"75","DOI":"10.18176\/jiaci.0338","article-title":"Systemic autoimmunity in a patient with candle syndrome","volume":"29","author":"Yamazaki-Nakashimada","year":"2019","journal-title":"J Investig Allergol Clin Immunol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1136\/annrheumdis-2020-219209","article-title":"Meta-analysis of 208370 east asians identifies 113 susceptibility loci for systemic lupus erythematosus","volume":"80","author":"Yin","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B52","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/ajmg.a.36887","article-title":"Characterization of human disease phenotypes associated with mutations in Trex1, Rnaseh2a, Rnaseh2b, Rnaseh2c, Samhd1, Adar, and Ifih1","author":"Crow","year":"2015","journal-title":"Am J Med Genet A"},{"key":"B53","doi-asserted-by":"publisher","first-page":"671","DOI":"10.3899\/jrheum.220513","article-title":"Genome-wide sequencing identified rare genetic variants for childhood-onset monogenic lupus","volume":"50","author":"Misztal","year":"2023","journal-title":"J Rheumatol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1086\/513443","article-title":"Heterozygous mutations in Trex1 cause familial chilblain lupus and dominant aicardi-goutieres syndrome","volume":"80","author":"Rice","year":"2007","journal-title":"Am J Hum Genet"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1177\/0883073811408310","article-title":"Aicardi-Goutieres syndrome and systemic lupus erythematosus (Sle) in a 12-year-old boy with Samhd1 mutations","volume":"26","author":"Ramantani","year":"2011","journal-title":"J Child Neurol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/ng.2933","article-title":"Gain-of-function mutations in Ifih1 cause a spectrum of human disease phenotypes associated with upregulated type I interferon signaling","volume":"46","author":"Rice","year":"2014","journal-title":"Nat Genet"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1038\/ng.2414","article-title":"Mutations in Adar1 cause aicardi-goutieres syndrome associated with a type I interferon signature","volume":"44","author":"Rice","year":"2012","journal-title":"Nat Genet"},{"key":"B58","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/ng.373","article-title":"Mutations involved in aicardi-goutieres syndrome implicate Samhd1 as regulator of the innate immune response","volume":"41","author":"Rice","year":"2009","journal-title":"Nat Genet"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.3899\/jrheum.171358","article-title":"Whole exome sequencing in early-onset systemic lupus erythematosus","volume":"45","author":"Batu","year":"2018","journal-title":"J Rheumatol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/ng2091","article-title":"Mutations in the gene encoding the 3'-5\u2019 DNA exonuclease Trex1 are associated with systemic lupus erythematosus","volume":"39","author":"Lee-Kirsch","year":"2007","journal-title":"Nat Genet"},{"key":"B61","doi-asserted-by":"publisher","first-page":"676082","DOI":"10.3389\/fimmu.2021.676082","article-title":"Ifn-I mediates lupus nephritis from the beginning to renal fibrosis","volume":"12","author":"Ding","year":"2021","journal-title":"Front Immunol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1182\/blood-2016-05-715987","article-title":"Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature","volume":"128","author":"Kavanagh","year":"2016","journal-title":"Blood"},{"key":"B63","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa1307361","article-title":"Early-Onset stroke and vasculopathy associated with mutations in Ada2","volume":"370","author":"Zhou","year":"2014","journal-title":"N Engl J Med"},{"key":"B64","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1056\/NEJMoa1307362","article-title":"Mutant adenosine deaminase 2 in a polyarteritis Nodosa vasculopathy","volume":"370","author":"Elkan","year":"2014","journal-title":"N Engl J Med"},{"key":"B65","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s11926-020-00944-1","article-title":"The many faces of a monogenic autoinflammatory disease: adenosine deaminase 2 deficiency","volume":"22","author":"Kendall","year":"2020","journal-title":"Curr Rheumatol Rep"},{"key":"B66","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1182\/blood.2018892752","article-title":"Deficiency of adenosine deaminase 2 triggers adenosine-mediated netosis and tnf production in patients with Dada2","volume":"134","author":"Carmona-Rivera","year":"2019","journal-title":"Blood"},{"key":"B67","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1053\/j.ajkd.2022.05.008","article-title":"A report of 2 cases of kidney involvement in Ada2 deficiency: different disease phenotypes and the tissue response to type I interferon","volume":"80","author":"Trivioli","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"B68","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3899\/jrheum.180045","article-title":"Variable clinical phenotypes and relation of interferon signature with disease activity in Ada2 deficiency","volume":"46","author":"Insalaco","year":"2019","journal-title":"J Rheumatol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"2020.06.21.162990","DOI":"10.1101\/2020.06.21.162990","article-title":"Ada2 is a lysosomal dnase regulating the type-I interferon response","author":"Greiner-Tollersrud","year":"2020","journal-title":"bioRxiv"},{"key":"B70","doi-asserted-by":"publisher","first-page":"eaba3688","DOI":"10.1126\/sciadv.aba3688","article-title":"Cellular sensing of extracellular purine nucleosides triggers an innate Ifn-Beta response","volume":"6","author":"Dhanwani","year":"2020","journal-title":"Sci Adv"},{"key":"B71","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s10875-018-0525-8","article-title":"Deficiency of adenosine deaminase 2 (Dada2): updates on the phenotype, genetics, pathogenesis, and treatment","volume":"38","author":"Meyts","year":"2018","journal-title":"J Clin Immunol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s00281-022-00918-8","article-title":"Mechanisms of vascular inflammation in deficiency of adenosine deaminase 2 (Dada2)","volume":"40","author":"Lee","year":"2022","journal-title":"Semin Immunopathol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/j.jaci.2019.12.908","article-title":"Genotype and functional correlates of disease phenotype in deficiency of adenosine deaminase 2 (Dada2)","volume":"145","author":"Lee","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1002\/art.40913","article-title":"Identification of novel adenosine deaminase 2 gene variants and varied clinical phenotype in pediatric vasculitis","volume":"71","author":"Gibson","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1016\/j.jaci.2021.10.030","article-title":"Tnf inhibition in vasculitis management in adenosine deaminase 2 deficiency (Dada2)","volume":"149","author":"Deuitch","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1056\/NEJMc1801927","article-title":"Treatment strategies for deficiency of adenosine deaminase 2","volume":"380","author":"Ombrello","year":"2019","journal-title":"N Engl J Med"},{"key":"B77","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jaci.2022.12.816","article-title":"Biologics and jak inhibitors for the treatment of monogenic systemic autoinflammatory diseases in children","volume":"151","author":"Du","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1002\/art.42087","article-title":"The 2021 European alliance of associations for rheumatology\/American college of rheumatology points to consider for diagnosis and management of autoinflammatory type I interferonopathies: Candle\/Praas, Savi, and Ags","volume":"74","author":"Cetin Gedik","year":"2022","journal-title":"Arthritis Rheumatol"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1169638\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T09:00:38Z","timestamp":1691571638000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1169638\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,9]]},"references-count":78,"alternative-id":["10.3389\/fped.2023.1169638"],"URL":"https:\/\/doi.org\/10.3389\/fped.2023.1169638","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,9]]},"article-number":"1169638"}}